PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-3.40
Negative P/E while Drug Manufacturers - Specialty & Generic median is -1.44. Seth Klarman would scrutinize path to profitability versus peers.
5.49
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.89. Jim Chanos would check for potential multiple compression risks.
0.33
P/B less than half the Drug Manufacturers - Specialty & Generic median of 0.81. Joel Greenblatt would investigate if assets are truly impaired. Check ROE versus peers.
-28.46
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -8.50. Seth Klarman would investigate cash flow improvement potential.
-28.46
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is -11.44. Seth Klarman would investigate operational improvement potential.
0.33
Fair value ratio less than half the Drug Manufacturers - Specialty & Generic median of 0.81. Joel Greenblatt would investigate if this discount is justified.
-7.36%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is -2.77%. Seth Klarman would investigate path to profitability.
-3.51%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -6.77%. Seth Klarman would investigate cash flow improvement potential.